Regeneron CEO discusses Praluent pricing and prescribing trends

Regeneron CEO discusses Praluent pricing and prescribing trends The passage only covers pharmaceutical pricing, market expectations, and physician survey data without linking any high‑profile political figures, intelligence agencies, or major power centers to misconduct. It offers no actionable leads for investigations into wrongdoing. Key insights: Leonard Schleifer, Regeneron CEO, defends Praluent pricing and access.; Praluent priced 46% above Evercore ISI forecast; sales could reach $4.8 B in 2020.; Physicians may prescribe Praluent to 30‑40% of post‑heart‑attack patients.